Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi, Ruth B Murray, Nasloon Ali, Trung N Tran, David Price, ISAR FIRE Working Group

Research output: Contribution to conferenceAbstractpeer-review

4 Downloads (Pure)

Abstract

Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.
Original languageEnglish
Publication statusAccepted/In press - 12 Mar 2021
EventATS International Conference Committee: ATS 2021 - Virtual event
Duration: 14 May 202119 May 2021
https://conference.thoracic.org/

Conference

ConferenceATS International Conference Committee
Period14/05/2119/05/21
Internet address

Fingerprint Dive into the research topics of 'Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)'. Together they form a unique fingerprint.

Cite this